CYP3A4 and breast carcinoma: Our study is the first to simultaneously determine the genotype of CYP3A4*4 A>G, CYP3A4*18B G>A and CYP3A4*22 C>T that may be useful as possible biomarkers to predict breast cancer response to treatment.